Department of Neurosciences, Neurosciences Intensive Care Unit, Medical University of South Carolina, Charleston, SC, USA.
Crit Care Med. 2013 May;41(5):1353-60. doi: 10.1097/CCM.0b013e31827ca4b3.
Intracranial hypertension and cerebral edema are known contributors to secondary brain injury and to poor neurologic outcomes. Small volume solutions of exceedingly high osmolarity, such as 23.4% saline, have been used for the management of intracranial hypertension crises and as a measure to prevent or reverse acute brain tissue shifts. We conducted a systematic literature review on the use of 23.4% saline in neurocritically ill patients and a meta-analysis of the effect of 23.4% saline on intracranial pressure reduction.
We searched computerized databases, reference lists, and personal files to identify all clinical studies in which 23.4% saline has been used for the treatment of neurocritical care patients. Studies that did not directly involve either effects on cerebral hemodynamics or the treatment of patients with clinical or radiographic evidence of intracranial hypertension and/or cerebral swelling were eliminated.
We identified 11 clinical studies meeting eligibility criteria. A meta-analysis was performed to evaluate the percent decrease in intracranial pressure and the 95% confidence intervals, from baseline to 60 minutes or nadir from the six studies from which this information could be extracted. A fixed effects meta-analysis estimated that the percent decrease in intracranial pressure from baseline to either 60 minutes or nadir after administration of 23.4% saline was 55.6% (se 5.90; 95% confidence interval, 43.99-67.12; p < 0.0001).
Highly concentrated hypertonic saline such as 23.4% provides a small volume solution with low cost and an over 50% reduction effect on raised intracranial pressure. Side effects reported are minor overall in view of the potentially catastrophic event that is being treated. High quality data are still needed to define the most appropriate osmotherapeutic agent, the optimal dose, the safest and most effective mode of administration and to further elucidate the mechanism of action of 23.4% saline and of osmotherapy in general.
颅内高压和脑水肿是继发性脑损伤和不良神经结局的已知因素。小容量超高渗溶液,如 23.4%盐水,已被用于治疗颅内高压危象,并作为预防或逆转急性脑组织移位的措施。我们对神经危重症患者使用 23.4%盐水的文献进行了系统评价,并对 23.4%盐水降低颅内压的效果进行了荟萃分析。
我们搜索了计算机数据库、参考文献列表和个人文件,以确定所有将 23.4%盐水用于神经危重症患者治疗的临床研究。未直接涉及脑血流动力学影响或治疗有临床或影像学证据的颅内高压和/或脑水肿患者的研究被排除在外。
我们确定了符合入选标准的 11 项临床研究。对其中 6 项可以提取相关信息的研究进行了荟萃分析,以评估颅内压从基线到 60 分钟或最低点的百分比降低情况,以及 95%置信区间。固定效应荟萃分析估计,从基线到给予 23.4%盐水后 60 分钟或最低点的颅内压百分比降低为 55.6%(se 5.90;95%置信区间,43.99-67.12;p < 0.0001)。
高浓度高渗盐水,如 23.4%盐水,提供了一种小容量、低成本的溶液,可使颅内压升高降低 50%以上。鉴于正在治疗的潜在灾难性事件,总体而言,报告的副作用较小。仍需要高质量的数据来确定最合适的渗透压治疗剂、最佳剂量、最安全有效的给药方式,并进一步阐明 23.4%盐水和一般渗透压治疗的作用机制。